Alere Company Profile (NYSE:ALR)

Alere trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALR."

Alere Inc (NYSE:ALR) issued its earnings results on Friday, November, 4th. The company reported $0.19 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.54 by $0.35. The business had revenue of $582 million for the quarter, compared to analyst estimates of $605.50 million. Alere had a positive return on equity of 8.01% and a negative net margin of 1.64%. The firm's revenue was down 3.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.10) EPS. View Alere's Earnings History.

6 brokerages have issued 12-month target prices for Alere's stock. Their forecasts range from $42.00 to $56.00. On average, they anticipate Alere's stock price to reach $49.60 in the next twelve months. View Analyst Ratings for Alere.

Here are some recent quotes from research analysts about Alere stock:

• 1. BTIG Research analysts commented, "Continued Growth in Infectious Disease Business Yesterday, Alere filed its preliminary unaudited 10-K and proxy statements following review of matters in South Korea and Japan, and expects to file their Form 10-K by June 15th, 2017. The preliminary financial statements included 4Q16 and FY2016 results, as well as re- statements for revenue recognition during 2014, 2015, and 2016. Topline preliminary 1Q17 financial results were also provided. The filing of the proxy indicates a decoupling process versus the 10-K filing, allowing the shareholder meeting to likely occur between mid-to-late July. The company must resolve outstanding accounting issues and file the 10K by June 15 th or face another negotiation with the creditors and bond holders. We remain Neutral as we continue to think that the deal with Abbott (ABT, Buy, $50PT) will close at the stated terms of $51 per share later this year." (5/24/2017)
• 2. According to Zacks Investment Research, "Alere Inc., formerly known as Inverness Medical Innovations, Inc., provides products and services, which focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts. " (4/19/2017)

Alere saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 1,289,823 shares, a decrease of 31.0% from the April 28th total of 1,869,308 shares. Based on an average trading volume of 2,382,140 shares, the short-interest ratio is currently 0.5 days. Currently, 1.5% of the shares of the stock are sold short.

Some companies that are related to Alere include PerkinElmer (PKI), Bio-Rad Laboratories (BIO), DexCom (DXCM), Icon Plc (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), VWR Corp (VWR), Bruker (BRKR), PAREXEL International (PRXL), EXACT Sciences (EXAS), WuXi PharmaTech (Cayman) (WX), Accelerate Diagnostics (AXDX), Abaxis (ABAX), Genomic Health (GHDX), Analogic (ALOG), BioTelemetry (BEAT), Heska Corp (HSKA) and China Cord Blood Corp (CO).

Alere's management team includes the folowing people:

• Gregg J. Powers, Independent Chairman of the Board
• Namal Nawana, President, Chief Executive Officer, Director
• James F. Hinrichs, Chief Financial Officer, Executive Vice President
• Daniella Cramp, Global President - Cardiometabolic Business Unit
• Sanjay Malkani, Global President - Toxicology
• Avi Pelossof, Global President - Infectious Disease Business Unit
• Ellen Chiniara J.D., Senior Vice President, General Counsel, Chief Ethics and Compliance Officer and Secretary
• John Bridgen Ph.D., Senior Vice President - Business Development
• Mark Gladwell, Senior Vice President - Global Operations
• Melissa Guerdan, Senior Vice President - Global Quality and Regulatory Assurance

Alere's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), Iridian Asset Management LLC CT (0.00%), Dimensional Fund Advisors LP (0.00%), Diamond Hill Capital Management Inc. (2.79%), USS Investment Management Ltd (0.00%) and First Eagle Investment Management LLC (1.58%). Company insiders that own Alere stock include James F Hinrichs, John Bridgen, Mark Gladwell, Melissa Guerdan, Robert Bernard Hargadon and Sanjay Malkani. View Institutional Ownership Trends for Alere.

Alere's stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, First Eagle Investment Management LLC, Cowen Group Inc., Jennison Associates LLC, York Capital Management Global Advisors LLC, Gabelli Funds LLC, Stonepine Capital Management LLC and Everett Capital Advisors UK LLP. View Insider Buying and Selling for Alere.

Alere's stock was bought by a variety of institutional investors in the last quarter, including Litespeed Management L.L.C., Renaissance Technologies LLC, Vanguard Group Inc., Laurion Capital Management LP, First Trust Advisors LP, Janus Capital Management LLC, Cornerstone Capital Management Holdings LLC. and Jane Street Group LLC. Company insiders that have bought Alere stock in the last two years include James F Hinrichs and Robert Bernard Hargadon. View Insider Buying and Selling for Alere.

Shares of Alere can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Alere stock can currently be purchased for approximately $48.82.